890130-35-5Relevant academic research and scientific papers
Synthesis and Biological Evaluation of Chromenylurea and Chromanylurea Derivatives as Anti-TNF-a agents that Target the p38 MAPK Pathway
Li, Xingzhou,Zhou, Xinming,Zhang, Jing,Wang, Lili,Long, Long,Zheng, Zhibing,Li, Song,Zhong, Wu
, p. 2004 - 2028 (2014/03/21)
A series of 1-aryl-3-(2H-chromen-5-yl)urea and 1-aryl-3-(chroman-5-yl)urea derivatives were designed, synthesized and evaluated for their inhibitory activities towards TNF-a production in lipopolysaccharide-stimulated THP-1 cells. The most active compound, 40g, inhibited TNF-a release with an IC50 value of 0.033 μM, which is equipotent to that of BIRB796 (IC50 = 0.032 μM).
1-Phenyl-5-pyrazolyl ureas: Potent and selective p38 kinase inhibitors
Dumas, Jacques,Hatoum-Mokdad, Holia,Sibley, Robert,Riedl, Bernd,Scott, William J.,Monahan, Mary Katherine,Lowinger, Timothy B.,Brennan, Catherine,Natero, Reina,Turner, Tiffany,Johnson, Jeffrey S.,Schoenleber, Robert,Bhargava, Ajay,Wilhelm, Scott M.,Housley, Timothy J.,Ranges, Gerald E.,Shrikhande, Alka
, p. 2051 - 2054 (2007/10/03)
Inhibitors of the MAP kinase p38 are potentially useful for the treatment of arthritis and osteoporosis. Several 2,3-dichlorophenyl ureas were identified as small-molecule inhibitors of p38 by a combinatorial chemistry effort. Optimization for cellular potency led to the discovery of a new class of potent and selective p38 kinase inhibitors, exemplified by the 1-phenyl-5-pyrazolyl urea 7 (IC50 = 13 nM). (C) 2000 Elsevier Science Ltd.
